

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding inducible nitric oxide synthase, wherein said antisense compound specifically hybridizes with and inhibits the expression of inducible nitric oxide synthase.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 19, 20, 21, 23, 24, 29, 30, 31, 32, 33, 36, 38, 42, 43, 44, 45, 46, 48, 49, 50, 52, 53, 54, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 98, 99, 100, 101, 103, 105, 106, 107, 109, 113, 117, 118, 125, 127, 131, 132, 135, 137, 138, 140, 148, 152, 153, 168 or 180.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. The antisense compound of claim 8 wherein the

2-1-83 / antisense oligonucleotide is a chimeric oligonucleotide.

11. A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition of claim 11 further comprising a colloidal dispersion system.

13. The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of inducible nitric oxide synthase in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

15. A method of treating a human having a disease or condition associated with inducible nitric oxide synthase comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of inducible nitric oxide synthase is inhibited.

16. The method of claim 15 wherein the disease or condition is diabetes.

17. The method of claim 15 wherein the disease or condition is an immunological disorder.

18. The method of claim 15 wherein the disease or condition is a cardiovascular disorder.

19. The method of claim 15 wherein the disease or condition is a neurologic disorder.

20. The method of claim 15 wherein the disease or condition is ischemia/reperfusion injury.